Web Desc
Antibodies as Drugs
joint with Targeted Cancer Therapies
Organizer(s): James D. Marks, E. Sally Ward and Louis M. Weiner
Date: March 27 - April 01, 2009
Location: Whistler Conference Centre, Whistler, BC, Canada
Sponsored by Pfizer Global Research & Development
Summary of Meeting:
Despite being theorized more than 100 years ago as the “magic bullets” to treat a range of diseases, it is only within the last 10 years that antibodies have become an important class of therapeutics. This meeting will bring together experts from academia and industry to discuss the current state of antibody therapeutics, their mechanism of action in a range of medical indications, novel approaches to improving discovery, manufacturing, formulation, and pharmacokinetics, methods to predict and increase therapeutic efficacy, as well as novel therapeutic opportunities in cancer, infectious diseases, allergy, inflammatory diseases, and the neurosciences. This meeting will be of interest to academic and industry scientists working in all these fields.
Scholarship Deadline: December 1 2008
Discounted Abstract Deadline: December 1 2008
Abstract Deadline: December 29 2008
Discounted Registration Deadline: January 27 2009
We gratefully acknowledge additional support for this conference from:
Biogen IdecLandes BiosciencePfizer Global Research & Development
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

CovX Research LLC (Pfizer)

Ensemble Discovery Corporation

f-star

Seattle Genetics, Inc.

Symphogen
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Cell PressLandes Bioscience
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Friday, March 27 | 3:00PM - 7:30PM
Registration
Room: Foyer


Friday, March 27 | 6:30PM - 7:30PM
Refreshments
Room: Foyer


Friday, March 27 | 7:30PM - 8:30PM
Keynote Address (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 1 of 3
* James D. Marks, University of California, San Francisco, USA

Friday, March 27 | 7:30PM - 8:30PM
Keynote Address (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 2 of 3
* Barbara L. Weber, Tango Therapeutics, USA

Friday, March 27 | 7:30PM - 8:30PM
Keynote Address (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 3 of 3
David P. Lane, Agency for Science, Technology and Research, Singapore
Target Validation in Cancer Treatment: The Use of Chemical Biology and Protein Aptamer Approaches

Saturday, March 28 | 7:00AM - 8:00AM
Breakfast
Room: Sea to Sky Ballroom A, Lower Level


Saturday, March 28 | 7:00AM - 8:00AM
Poster Setup
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Saturday, March 28 | 8:00AM - 11:15AM
Novel Cancer Drug Scaffolds (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 1 of 8
* James E. Bradner, Novartis Institutes for BioMedical Research, USA

Saturday, March 28 | 8:00AM - 11:15AM
Novel Cancer Drug Scaffolds (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 2 of 8
* James D. Marks, University of California, San Francisco, USA

Saturday, March 28 | 8:00AM - 11:15AM
Novel Cancer Drug Scaffolds (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 3 of 8
Andreas G. Plückthun, University of Zürich, Switzerland
Ankyrin Repeat Proteins

Saturday, March 28 | 8:00AM - 11:15AM
Novel Cancer Drug Scaffolds (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 4 of 8
Nick Terrett, Ensemble Discovery Corporation, USA
A DNA-Programmed Chemistry Approach to Macrocyclic Lead Compounds

Saturday, March 28 | 8:00AM - 11:15AM
Novel Cancer Drug Scaffolds (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 5 of 8
Gregory L. Verdine, Harvard University, USA
Drugging “Undruggable” Targets Using Stapled Peptides

Saturday, March 28 | 8:00AM - 11:15AM
Novel Cancer Drug Scaffolds (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 6 of 8
Rodney W. Lappe, CovX Research LLC, Pfizer, USA
Using CovX-Body Technology to Target the Angiopoietin Axis

Saturday, March 28 | 8:00AM - 11:15AM
Novel Cancer Drug Scaffolds (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 7 of 8
Yollete V. Guillen Schlippe, Massachusetts General Hospital, USA
Short Talk: Selection of Cyclic Peptides Composed of Multiple Unnatural Amino Acids that Display Antibody-Like Affinity

Saturday, March 28 | 8:00AM - 11:15AM
Novel Cancer Drug Scaffolds (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 8 of 8
Jennifer R. Cochran, Stanford University, USA
Short Talk: Engineered Knottin Peptides: A New Class of Agents for Imaging Integrin Expression in Living Subjects

Saturday, March 28 | 9:20AM - 9:40AM
Coffee Break
Room: Foyer


Saturday, March 28 | 11:15AM - 12:00PM
Lunch
Room: Foyer/Sea to Sky Ballroom A


Saturday, March 28 | 12:00PM - 2:30PM
Poster Session 1
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Saturday, March 28 | 2:30PM - 4:30PM
Workshop 1: Novel Approaches to Cancer Drug Development (Joi
nt)
Room: Sea to Sky Ballroom C

Speaker 1 of 6
* Louis M. Weiner, Georgetown University Medical Center, USA

Saturday, March 28 | 2:30PM - 4:30PM
Workshop 1: Novel Approaches to Cancer Drug Development (Joi
nt)
Room: Sea to Sky Ballroom C

Speaker 2 of 6
Steve K. Horrigan, Avalon Pharmaceuticals, USA
Systems Biology for Lead Optimization

Saturday, March 28 | 2:30PM - 4:30PM
Workshop 1: Novel Approaches to Cancer Drug Development (Joi
nt)
Room: Sea to Sky Ballroom C

Speaker 3 of 6
Lutz Jermutus, MedImmune LLC, UK
Discovering Cancer Therapeutics by Phage and Ribosome Display as well as Transgenics Technologies

Saturday, March 28 | 2:30PM - 4:30PM
Workshop 1: Novel Approaches to Cancer Drug Development (Joi
nt)
Room: Sea to Sky Ballroom C

Speaker 4 of 6
Ravi Majeti, Stanford University, USA
Blocking Monoclonal Antibodies Directed Against CD47 Preferentially Enable Phagocytosis and Elimination of Human Acute Myeloid Leukemia Stem Cells

Saturday, March 28 | 2:30PM - 4:30PM
Workshop 1: Novel Approaches to Cancer Drug Development (Joi
nt)
Room: Sea to Sky Ballroom C

Speaker 5 of 6
Teemu T. Junttila, Genentech, Inc., USA
Superior in vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2 Amplified Breast Cancer

Saturday, March 28 | 2:30PM - 4:30PM
Workshop 1: Novel Approaches to Cancer Drug Development (Joi
nt)
Room: Sea to Sky Ballroom C

Speaker 6 of 6
Mariia Yuneva, Francis Crick Institute, UK
Combining Metabolomics with Microarray Analysis to Determine Metabolic Cancer Targets in vivo

Saturday, March 28 | 4:30PM - 5:00PM
Coffee Available
Room: Foyer


Saturday, March 28 | 5:00PM - 7:00PM
Generating and Engineering Novel Antibody Binding Sites
Room: Sea to Sky Ballroom B

Speaker 1 of 5
* Lutz Jermutus, MedImmune LLC, UK

Saturday, March 28 | 5:00PM - 7:00PM
Generating and Engineering Novel Antibody Binding Sites
Room: Sea to Sky Ballroom B

Speaker 2 of 5
George Georgiou, University of Texas at Austin, USA
Selection, Fc Engineering and Preparative Expression of Full Length IgG in E.coli

Saturday, March 28 | 5:00PM - 7:00PM
Generating and Engineering Novel Antibody Binding Sites
Room: Sea to Sky Ballroom B

Speaker 3 of 5
James D. Marks, University of California, San Francisco, USA
Selecting Internalizing Antibodies for Drug Delivery

Saturday, March 28 | 5:00PM - 7:00PM
Generating and Engineering Novel Antibody Binding Sites
Room: Sea to Sky Ballroom B

Speaker 4 of 5
Max Woisetschlager, F-Star, Austria
Antigen Binding by Modified Immunoglobulin Fc (Fcab) and Complete IgGs with Additional Binding Sites

Saturday, March 28 | 5:00PM - 7:00PM
Generating and Engineering Novel Antibody Binding Sites
Room: Sea to Sky Ballroom B

Speaker 5 of 5
Roger R. Beerli, NBE-Therapeutics AG, Switzerland
Short Talk: Isolation and Preclinical Validation of Therapeutic Human Monoclonal Antibodies Isolated by Mammalian Cell Display

Saturday, March 28 | 5:00PM - 7:15PM
The Chemistry of Targeted Drug Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 1 of 6
* Gregory L. Verdine, Harvard University, USA


Saturday, March 28 | 5:00PM - 7:15PM
The Chemistry of Targeted Drug Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 2 of 6
James E. Bradner, Novartis Institutes for BioMedical Research, USA
Next-Generation Histone Deacetylase Inhibitors


Saturday, March 28 | 5:00PM - 7:15PM
The Chemistry of Targeted Drug Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 3 of 6
Saul H. Rosenberg, Abbott Laboratories, USA
Targeting Apoptosis: Bcl-2 Family Protein Inhibitors


Saturday, March 28 | 5:00PM - 7:15PM
The Chemistry of Targeted Drug Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 4 of 6
Nathanael Gray, Stanford University, USA
Tackling the Kinome: Bcr-Abl, EML4-ALK in EGFR


Saturday, March 28 | 5:00PM - 7:15PM
The Chemistry of Targeted Drug Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 5 of 6
Kathlynn C. Brown, University of Texas Southwestern Medical Center, USA
Short Talk: Isolation of a Suite of Cell Binding Peptides: Novel Ligands for Diagnosis and Targeted Therapy for Non-Small Cell Lung Cancer


Saturday, March 28 | 5:00PM - 7:15PM
The Chemistry of Targeted Drug Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 6 of 6
Suzanne Forry-Schaudies, National Cancer Institute, National Institutes of Health, USA
Short Talk: NCI Chemical Biology Consortium (CBC)


Saturday, March 28 | 7:00PM - 7:00PM
On Own for Dinner


Sunday, March 29 | 7:00AM - 8:00AM
Breakfast
Room: Sea to Sky Ballroom A, Lower Level


Sunday, March 29 | 8:00AM - 11:15AM
Engineering Fc Regions for Optimized ADCC and PK
Room: Sea to Sky Ballroom B

Speaker 1 of 7
* Raphael Clynes, Xencor, Inc., USA

Sunday, March 29 | 8:00AM - 11:15AM
Engineering Fc Regions for Optimized ADCC and PK
Room: Sea to Sky Ballroom B

Speaker 2 of 7
Louis M. Weiner, Georgetown University Medical Center, USA
Optimizing in vitro and in vivo ADCC for Cancer Therapy

Sunday, March 29 | 8:00AM - 11:15AM
Engineering Fc Regions for Optimized ADCC and PK
Room: Sea to Sky Ballroom B

Speaker 3 of 7
John R. Desjarlais, Xencor, Inc., USA
Engineered Fc Domains for Enhanced Cytotoxicity and Pharmacokinetics

Sunday, March 29 | 8:00AM - 11:15AM
Engineering Fc Regions for Optimized ADCC and PK
Room: Sea to Sky Ballroom B

Speaker 4 of 7
Pablo Umaña, Roche Innovation Center Zürich, Switzerland
New Glycoengineered Antibodies with Enhanced Effector Functions

Sunday, March 29 | 8:00AM - 11:15AM
Engineering Fc Regions for Optimized ADCC and PK
Room: Sea to Sky Ballroom B

Speaker 5 of 7
E. Sally Ward, University of Texas Southwestern Medical Center, USA
The Role of FcRn in IgG Homeostasis: Implications for the Use of Antibodies in Therapy

Sunday, March 29 | 8:00AM - 11:15AM
Engineering Fc Regions for Optimized ADCC and PK
Room: Sea to Sky Ballroom B

Speaker 6 of 7
Jeanette H.W. Leusen, University Medical Center Utrecht, Netherlands
Short Talk: The Fc Receptor gamma-Chain ITAM is Required for Antibody Immunotherapy

Sunday, March 29 | 8:00AM - 11:15AM
Engineering Fc Regions for Optimized ADCC and PK
Room: Sea to Sky Ballroom B

Speaker 7 of 7
Shu-ichi Hashimoto, Chiome Bioscience Inc., Japan
Short Talk: ADLib System: New Antibody Generating Technology based on Cell Surface Displayed Antibody Library

Sunday, March 29 | 8:00AM - 11:15AM
Cancer Targets
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 1 of 7
* Gordon B. Mills, University of Texas MD Anderson Cancer Center, USA


Sunday, March 29 | 8:00AM - 11:15AM
Cancer Targets
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 2 of 7
Craig B. Thompson, Memorial Sloan Kettering Cancer Center, USA
Mitochondrial Targets


Sunday, March 29 | 8:00AM - 11:15AM
Cancer Targets
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 3 of 7
Pierre Sonveaux, University of Louvain, Belgium
Lactate-Fueled Tumor Cell Respiration: A New Paradigm and a New Target for Therapy


Sunday, March 29 | 8:00AM - 11:15AM
Cancer Targets
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 4 of 7
Neal Rosen, Memorial Sloan-Kettering Cancer Center, USA
Role of Feedback and Redundancy in Oncoprotein Activated Signaling Pathways


Sunday, March 29 | 8:00AM - 11:15AM
Cancer Targets
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 5 of 7
D. Gary Gilliland, Merck & Co., Inc., USA
Genome Wide shRNA-Based Synthetic Lethality Screens to Target 'Undruggable' Cancer Disease Alleles


Sunday, March 29 | 8:00AM - 11:15AM
Cancer Targets
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 6 of 7
Daniel Monticello, Molecular Logix Inc, USA
Short Talk: Development of a Pan-HER Dominant Negative Ligand that Inhibits HER Phosphorylation and HER-Ligand Dependent Tumor Cell Growth


Sunday, March 29 | 8:00AM - 11:15AM
Cancer Targets
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 7 of 7
Peter R. Rhode, Altor BioScience Corp., USA
Short Talk: IL-15 Superagonist as a Targeted Immunotherapeutic Molecule


Sunday, March 29 | 9:20AM - 9:40AM
Coffee Break
Room: Foyer


Sunday, March 29 | 11:15AM - 11:15AM
On Own for Lunch


Sunday, March 29 | 11:15AM - 1:00PM
Poster Setup
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Sunday, March 29 | 1:00PM - 10:00PM
Poster Viewing
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Sunday, March 29 | 2:30PM - 4:30PM
Workshop 2: Bispecific Antibodies and Antibody Combinations:
The How and the Why
Room: Sea to Sky Ballroom B

Speaker 1 of 8
* James D. Marks, University of California, San Francisco, USA

Sunday, March 29 | 2:30PM - 4:30PM
Workshop 2: Bispecific Antibodies and Antibody Combinations:
The How and the Why
Room: Sea to Sky Ballroom B

Speaker 2 of 8
Robert Mabry, ZymoGenetics, Inc., USA
Selection of Stable Antibody Fragments for Assembly of Dual-Targeting Therapeutics

Sunday, March 29 | 2:30PM - 4:30PM
Workshop 2: Bispecific Antibodies and Antibody Combinations:
The How and the Why
Room: Sea to Sky Ballroom B

Speaker 3 of 8
Carston R. Wagner, University of Minnesota, USA
Chemically Controlled Assembly of Single-Chain Antibody Nanorings

Sunday, March 29 | 2:30PM - 4:30PM
Workshop 2: Bispecific Antibodies and Antibody Combinations:
The How and the Why
Room: Sea to Sky Ballroom B

Speaker 4 of 8
Wei Yan, Amgen Inc., USA
Design and Engineering of Fc Heterodimers for the Production of Bispecific Antibodies

Sunday, March 29 | 2:30PM - 4:30PM
Workshop 2: Bispecific Antibodies and Antibody Combinations:
The How and the Why
Room: Sea to Sky Ballroom B

Speaker 5 of 8
Aran Frank Labrijn, Genmab, Netherlands
Therapeutic IgG4 Antibodies Engage in Fab-Arm Exchange with Patient’s IgG4 in vivo

Sunday, March 29 | 2:30PM - 4:30PM
Workshop 2: Bispecific Antibodies and Antibody Combinations:
The How and the Why
Room: Sea to Sky Ballroom B

Speaker 6 of 8
Ann P. MacLaren, Biogen Idec, USA
A Novel Tetravalent Anti-CD23 Antibody Induces Potent Anti-Tumor Activity in CD23+ Tumor Cells via Hyper Cross-Linking of CD23

Sunday, March 29 | 2:30PM - 4:30PM
Workshop 2: Bispecific Antibodies and Antibody Combinations:
The How and the Why
Room: Sea to Sky Ballroom B

Speaker 7 of 8
Klaus Koefoed, Symphogen A/S, Denmark
Development of Sym004 - a Dual Antibody Combination Targeting the Epidermal Growth Factor Receptor with Strong Anti-Tumor Efficacy in a Xenograft Mouse Model

Sunday, March 29 | 2:30PM - 4:30PM
Workshop 2: Bispecific Antibodies and Antibody Combinations:
The How and the Why
Room: Sea to Sky Ballroom B

Speaker 8 of 8
Rob Roovers, Merus BV, Netherlands
Combining Different Modes of EGFR Inhibition into a Single Nanobody-Based Molecule Yields a Promising Anti-Cancer Drug

Sunday, March 29 | 4:30PM - 5:00PM
Coffee Available
Room: Foyer


Sunday, March 29 | 5:00PM - 7:00PM
Immune System Activation to Elicit Therapeutic Responses
Room: Sea to Sky Ballroom B

Speaker 1 of 5
* E. Sally Ward, University of Texas Southwestern Medical Center, USA

Sunday, March 29 | 5:00PM - 7:00PM
Immune System Activation to Elicit Therapeutic Responses
Room: Sea to Sky Ballroom B

Speaker 2 of 5
Raphael Clynes, Xencor, Inc., USA
Conversion of Passive Antibody Therapy to Active Immunity

Sunday, March 29 | 5:00PM - 7:00PM
Immune System Activation to Elicit Therapeutic Responses
Room: Sea to Sky Ballroom B

Speaker 3 of 5
Gerard Zurawski, Baylor Institute for Immunology Research, USA
Vaccines Based on Targeting Antigens Directly to DCs

Sunday, March 29 | 5:00PM - 7:00PM
Immune System Activation to Elicit Therapeutic Responses
Room: Sea to Sky Ballroom B

Speaker 4 of 5
Kavita Dhodapkar, Emory University, USA
Antibody-Based Induction of Adaptive Immune Response

Sunday, March 29 | 5:00PM - 7:00PM
Immune System Activation to Elicit Therapeutic Responses
Room: Sea to Sky Ballroom B

Speaker 5 of 5
Mark S. Cragg, University of Southampton, UK
Short Talk: The Role of Activatory and Inhibitory FcgR in Antibody Immunotherapy

Sunday, March 29 | 5:00PM - 7:00PM
Autophagy and Metabolism
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 1 of 3
Matthew G. Vander Heiden, Massachusetts Institute of Technology, USA
Targeting Cancer Cell Metabolism


Sunday, March 29 | 5:00PM - 7:00PM
Autophagy and Metabolism
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 2 of 3
Gordon B. Mills, University of Texas MD Anderson Cancer Center, USA
Targeting Energy Sensing


Sunday, March 29 | 5:00PM - 7:00PM
Autophagy and Metabolism
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 3 of 3
Chi Van Dang, University of Pennsylvania, USA
Therapeutic Implications of the Warburg Effect


Sunday, March 29 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Sunday, March 29 | 7:30PM - 10:00PM
Poster Session 2
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Monday, March 30 | 7:00AM - 8:00AM
Breakfast
Room: Sea to Sky Ballroom A, Lower Level


Monday, March 30 | 8:00AM - 11:15AM
Antibodies for Treatment of Cancer
Room: Sea to Sky Ballroom B

Speaker 1 of 7
* Louis M. Weiner, Georgetown University Medical Center, USA

Monday, March 30 | 8:00AM - 11:15AM
Antibodies for Treatment of Cancer
Room: Sea to Sky Ballroom B

Speaker 2 of 7
Mark X. Sliwkowski, Genentech, Inc., USA
HER2 Targeted Therapies

Monday, March 30 | 8:00AM - 11:15AM
Antibodies for Treatment of Cancer
Room: Sea to Sky Ballroom B

Speaker 3 of 7
Andrew M. Scott, Ludwig Institute for Cancer Research, Australia
Targeting a Novel EGFR Epitope on Cancer Cells

Monday, March 30 | 8:00AM - 11:15AM
Antibodies for Treatment of Cancer
Room: Sea to Sky Ballroom B

Speaker 4 of 7
Kerry A. Chester, University College London Cancer Institute, UK
Antibody-Directed Enzyme Prodrug Therapy (ADEPT) of Cancer

Monday, March 30 | 8:00AM - 11:15AM
Antibodies for Treatment of Cancer
Room: Sea to Sky Ballroom B

Speaker 5 of 7
Philip E. Thorpe, University of Texas Southwestern Medical Center, USA
Targeting Exposed Phosphatidylserine on Cancer Blood Vessels: Preclinical and Clinical Studies

Monday, March 30 | 8:00AM - 11:15AM
Antibodies for Treatment of Cancer
Room: Sea to Sky Ballroom B

Speaker 6 of 7
Kelly J. Davis, Massachusetts Institute of Technology, USA
Short Talk: Antibody with Picomolar Affinity to DOTA Chelates of Multiple Radionuclides for Pretargeted Radioimmunotherapy

Monday, March 30 | 8:00AM - 11:15AM
Antibodies for Treatment of Cancer
Room: Sea to Sky Ballroom B

Speaker 7 of 7
Mitsuo Satoh, Research Division, Kyowa Hakko Kirin Company Ltd., Japan
Short Talk: Non-Fucosylated Rituximab Potentiates Human Neutrophil Phagocytosis through its High Binding for FcgammaRIIIb and MHC Class II Expression on the Phagocytotic Neutrophils

Monday, March 30 | 8:00AM - 11:15AM
Novel Target Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 1 of 7
* D. Gary Gilliland, Merck & Co., Inc., USA


Monday, March 30 | 8:00AM - 11:15AM
Novel Target Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 2 of 7
Alan Ashworth, University of California, San Francisco, USA
Synthetic Lethal Approaches to the Development of New Therapies Targeting DNA Repair Deficiencies in Cancer


Monday, March 30 | 8:00AM - 11:15AM
Novel Target Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 3 of 7
William G. Kaelin, Jr., Dana-Farber Cancer Institute, USA
Therapeutic Targets Emerging from Studies of the VHL Tumor Suppressor Protein and 2-Oxoglutarate Dependent Dioxygenases


Monday, March 30 | 8:00AM - 11:15AM
Novel Target Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 4 of 7
Peter A. Jones, Van Andel Research Institute, USA
Epigenetic Therapy


Monday, March 30 | 8:00AM - 11:15AM
Novel Target Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 5 of 7
Lynda Chin, University of Texas MD Anderson Cancer Center, USA
Mining and Translating the Cancer Genome


Monday, March 30 | 8:00AM - 11:15AM
Novel Target Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 6 of 7
Igor Landais, Oregon Health Sciences University, USA
Short Talk: Identification of Potent Inhibitors of the Fanconi Anemia Pathway Using a Novel Cell-Free Assay


Monday, March 30 | 8:00AM - 11:15AM
Novel Target Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 7 of 7
Johannes Zuber, Research Institute of Molecular Pathology, Austria
Short Talk: In-vivo Evaluation of Putative Drug Targets in Chemotherapy-Resistant MLL/AF9-Induced Acute Myeloid Leukemia Using Tet-Regulatable RNAi


Monday, March 30 | 9:20AM - 9:40AM
Coffee Break
Room: Foyer


Monday, March 30 | 11:15AM - 1:00PM
Poster Setup
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Monday, March 30 | 11:15AM - 11:15AM
On Own for Lunch


Monday, March 30 | 1:00PM - 10:00PM
Poster Viewing
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Monday, March 30 | 2:30PM - 4:30PM
Workshop 3: Therapeutic Antibodies in the Neurosciences
Room: Sea to Sky Ballroom B

Speaker 1 of 4
* Eric V. Shusta, University of Wisconsin-Madison, USA
Antibodies and the Blood-Brain Barrier

Monday, March 30 | 2:30PM - 4:30PM
Workshop 3: Therapeutic Antibodies in the Neurosciences
Room: Sea to Sky Ballroom B

Speaker 2 of 4
Anne Messer, Wadsworth Center, USA
Intrabodies for Neurodegeneration Disorders

Monday, March 30 | 2:30PM - 4:30PM
Workshop 3: Therapeutic Antibodies in the Neurosciences
Room: Sea to Sky Ballroom B

Speaker 3 of 4
Anthony Williamson, Calmune Corporation, USA
Antibodies for Prion Based Diseases

Monday, March 30 | 2:30PM - 4:30PM
Workshop 3: Therapeutic Antibodies in the Neurosciences
Room: Sea to Sky Ballroom B

Speaker 4 of 4
Angela R. Jones, University of Wisconsin - Madison, USA
Short Talk: Identification of Blood-Brain Barrier Targeting and Transporting Antibodies

Monday, March 30 | 4:30PM - 5:00PM
Coffee Available
Room: Foyer


Monday, March 30 | 5:00PM - 7:00PM
Identifying and Predicting Antibody Efficacy and Toxicity
Room: Sea to Sky Ballroom B

Speaker 1 of 5
* Andrew M. Scott, Ludwig Institute for Cancer Research, Australia

Monday, March 30 | 5:00PM - 7:00PM
Identifying and Predicting Antibody Efficacy and Toxicity
Room: Sea to Sky Ballroom B

Speaker 2 of 5
Peter D. Senter, Seattle Genetics Inc., USA
Antibody Drug Conjugates for Cancer Therapy

Monday, March 30 | 5:00PM - 7:00PM
Identifying and Predicting Antibody Efficacy and Toxicity
Room: Sea to Sky Ballroom B

Speaker 3 of 5
Birgit Schoeberl, Novartis Institutes for BioMedical Research, USA
An Attempt to Translate in vitro Responses into the Clinic Using Computationally Predicted Preclinical Data from ErbB Targeted Therapies

Monday, March 30 | 5:00PM - 7:00PM
Identifying and Predicting Antibody Efficacy and Toxicity
Room: Sea to Sky Ballroom B

Speaker 4 of 5
Richard H.J. Begent, University College London, UK
Guidelines for Information about Antibody Therapy Experiments; Lessons from the Tegenero Experience

Monday, March 30 | 5:00PM - 7:00PM
Identifying and Predicting Antibody Efficacy and Toxicity
Room: Sea to Sky Ballroom B

Speaker 5 of 5
Max Warncke, Novartis, Switzerland
Short Talk: Effector Functions of Human IgG Subclasses for Non-Human Primate FcgR

Monday, March 30 | 5:00PM - 7:15PM
Target Validation
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 1 of 6
* William G. Kaelin, Jr., Dana-Farber Cancer Institute, USA


Monday, March 30 | 5:00PM - 7:15PM
Target Validation
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 2 of 6
Dean Walton Felsher, Stanford University, USA
Validating Cancer Targets using Conditional Transgenic Mouse Models


Monday, March 30 | 5:00PM - 7:15PM
Target Validation
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 3 of 6
Scott W. Lowe, Memorial Sloan Kettering Cancer Center, USA
Dissecting Tumor Suppressor Gene Networks in vivo


Monday, March 30 | 5:00PM - 7:15PM
Target Validation
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 4 of 6
Peter J. Houghton, St. Jude Children's Research Hospital, USA
Tumor Xenografts for Target Validation


Monday, March 30 | 5:00PM - 7:15PM
Target Validation
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 5 of 6
Poulikos I. Poulikakos, Icahn School of Medicine at Mount Sinai, USA
Short Talk: ATP-Competitive Inhibitors of RAF Kinase Inhibit ERK Signaling in Cells Harboring Mutant BRAF, but Activate ERK Signaling in Cells with Wild Type BRAF


Monday, March 30 | 5:00PM - 7:15PM
Target Validation
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 6 of 6
Amy R. Rappaport, Cold Spring Harbor Laboratory, USA
Short Talk: MLL/AF9 is Required for the Maintenance of Aggressive Acute Myeloid Leukemia in Mice


Monday, March 30 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Monday, March 30 | 7:30PM - 10:00PM
Poster Session 3
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Tuesday, March 31 | 7:00AM - 8:00AM
Breakfast
Room: Sea to Sky Ballroom A, Lower Level


Tuesday, March 31 | 8:00AM - 11:15AM
Antibodies in the Treatment of Autoimmunity, Allergy and Inf
ectious Diseases

Room: Sea to Sky Ballroom B

Speaker 1 of 6
* James D. Marks, University of California, San Francisco, USA

Tuesday, March 31 | 8:00AM - 11:15AM
Antibodies in the Treatment of Autoimmunity, Allergy and Inf
ectious Diseases

Room: Sea to Sky Ballroom B

Speaker 2 of 6
Ian A. Wilson, The Scripps Research Institute, USA
Structural Aspects of Antibody Recognition of Influenza

Tuesday, March 31 | 8:00AM - 11:15AM
Antibodies in the Treatment of Autoimmunity, Allergy and Inf
ectious Diseases

Room: Sea to Sky Ballroom B

Speaker 3 of 6
Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland
Human Monoclonal Antibodies from Memory B cells

Tuesday, March 31 | 8:00AM - 11:15AM
Antibodies in the Treatment of Autoimmunity, Allergy and Inf
ectious Diseases

Room: Sea to Sky Ballroom B

Speaker 4 of 6
Dennis R. Burton, The Scripps Research Institute, USA
Antibodies for HIV Therapy and Vaccine Development

Tuesday, March 31 | 8:00AM - 11:15AM
Antibodies in the Treatment of Autoimmunity, Allergy and Inf
ectious Diseases

Room: Sea to Sky Ballroom B

Speaker 5 of 6
John Haurum, Imclone, USA
Capturing the Natural Humoral Immune Response by Symplex

Tuesday, March 31 | 8:00AM - 11:15AM
Antibodies in the Treatment of Autoimmunity, Allergy and Inf
ectious Diseases

Room: Sea to Sky Ballroom B

Speaker 6 of 6
Tariq Ghayur, AbbVie, Inc., USA
Dual Variable Domain Immunoglobulins (DVD-Ig TM): A Novel Class of Dual-Specific Biologics

Tuesday, March 31 | 8:00AM - 11:00AM
Translating Targeted Therapy to the Clinic
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 1 of 7
* Lynda Chin, University of Texas MD Anderson Cancer Center, USA


Tuesday, March 31 | 8:00AM - 11:00AM
Translating Targeted Therapy to the Clinic
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 2 of 7
Alan Colowick, Gloucester Pharmaceuticals, USA
Clinical Activity of Romidepsin, a pan-HDACi, in the Clinic


Tuesday, March 31 | 8:00AM - 11:00AM
Translating Targeted Therapy to the Clinic
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 3 of 7
Barbara L. Weber, Tango Therapeutics, USA
Using Cancer Genomics to Inform Targeted Drug Development


Tuesday, March 31 | 8:00AM - 11:00AM
Translating Targeted Therapy to the Clinic
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 4 of 7
Tak W. Mak, Campbell Family Institute for Breast Cancer, Canada
Cancer Metabolism: Back to the Future


Tuesday, March 31 | 8:00AM - 11:00AM
Translating Targeted Therapy to the Clinic
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 5 of 7
Alice Fan, Stanford University, USA
Talk Title to be Determined


Tuesday, March 31 | 8:00AM - 11:00AM
Translating Targeted Therapy to the Clinic
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 6 of 7
Paul Spellman, Lawrence Berkeley National Laboratory, USA
Talk Title to be Determined


Tuesday, March 31 | 8:00AM - 11:00AM
Translating Targeted Therapy to the Clinic
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 7 of 7
Phillip G. Febbo, Illumina, Inc., USA
Short Talk: MYC Activity Mitigates Response to Rapamycin in Prostate Cancer through 4EBP1-Mediated Inhibition of Autophagy


Tuesday, March 31 | 9:20AM - 9:40AM
Coffee Break
Room: Foyer


Tuesday, March 31 | 11:15AM - 11:15AM
On Own for Lunch


Tuesday, March 31 | 4:30PM - 5:00PM
Coffee Available
Room: Foyer


Tuesday, March 31 | 5:00PM - 7:00PM
Imaging in Cancer Drug Discovery (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 1 of 5
* E. Sally Ward, University of Texas Southwestern Medical Center, USA

Tuesday, March 31 | 5:00PM - 7:00PM
Imaging in Cancer Drug Discovery (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 2 of 5
* Roger Y. Tsien, HHMI/University of California, San Diego, USA
Optical and MR Imaging of Tumors in vivo with Activatable Cell Penetrating Peptides

Tuesday, March 31 | 5:00PM - 7:00PM
Imaging in Cancer Drug Discovery (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 3 of 5
Karl Dane Wittrup, Massachusetts Institute of Technology, USA
Pretargeted Radioimmunotherapy: Predictive Modeling and Experimental Validation

Tuesday, March 31 | 5:00PM - 7:00PM
Imaging in Cancer Drug Discovery (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 4 of 5
Anna M. Wu, University of California, Los Angeles, USA
Engineered Antibodies for Probing Cell Surface Markers in vivo

Tuesday, March 31 | 5:00PM - 7:00PM
Imaging in Cancer Drug Discovery (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 5 of 5
Sripad Ram, University of Texas Southwestern Medical Center, USA
Short Talk: 3D Single Molecule Tracking of Antibodies in Live Cells Using Multifocal Plane Microscopy

Tuesday, March 31 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Tuesday, March 31 | 8:00PM - 11:00PM
Entertainment
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Tuesday, March 31 | 8:00PM - 11:00PM
Cash Bar
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Wednesday, April 01 | 10:25AM - 10:25AM
Departure


*Session Chair.